Literature DB >> 25006533

Influence of dyslipidemia in control of arterial hypertension among type-2 diabetics in the western region of the Republic of Macedonia.

Ylber Jani1, Amet Kamberi1, Fatmir Ferati2, Atila Rexhepi2, Bekim Pocesta3, Nikola Orovcanec4, Dali Lala5, Gafur Polisi6, Mair Iseni7, Arben Mirto8, Agim Zeqiri9.   

Abstract

OBJECTIVE: To determine the influence of dyslipidemia in control of blood pressure in patients with type 2 Diabetes. To test the hypothesis that, blood pressure and lipid levels are not sufficiently controlled in patients with type 2 Diabetes, in the western region of the Republic of Macedonia.
BACKGROUND: Abnormalities of lipid and lipoprotein levels in the serum (dyslipidemia) are recognized as major modifiable cardiovascular disease risk factors and have been identified as independent risk factors for essential hypertension, giving rise to the term dyslipidemic hypertension. While patient-related data from primary care that demonstrate an under-treatment of blood pressure and dyslipidemia in type 2 Diabetics are vastly available in clinical practice, results from population-based studies are scarce.
MATERIAL AND METHODS: The study was conducted on outpatients in Primary Health Care Clinics in 8 cities on the western region of the Republic of Macedonia. Prospectively the tests were performed on 600 (45.6% women and 54.4% men) participants with a mean age of 62 ± 5.8. Study participants were selected among primary care patients, who were actively on therapy for diabetes mellitus and hypertension during the period of March 2013 - March 2014. Patients' demographic characteristics, clinical laboratory and drug usage data were obtained. The patients were classified according to the BP control, into 2 groups.
RESULTS: A total of 600 patients, of which 45.6% female and 54.3% male, completed the survey and had data for a 1-year medical record review. It was observed that a high percentage, 65.3% of patients, did not have controlled blood pressure despite the ongoing medical treatment, according to evidence and current guidelines in a cohort of hypertensive diabetics. (Chi-square: 19.85, p<0.001). Among participants with controled BP, untreated or insufficiently treated dyslipidemia was recorded in 23% of them, whereas among participants with uncontrolled BP, untreated or insufficiently treated dyslipidemia was recorded in 67% of the participants. (Chi-square: 15.01, p=0.0001).
CONCLUSION: A significant influence of dyslipidemia on the control of blood pressure in patients with type 2 Diabetes, was observed in our study. In a small country as Republic of Macedonia (with a population of around 2.000.000, especially the western region with approximately 1/2 of the overall population), this study highlights the considerable lack of awareness and insufficient management of the most important preventable and treatable cardiovascular risk factors (hypertension and dyslipidemia). These findings provide a possible explanation of the steadily high cardiovascular mortality rate despite the clinical and therapeutic progress and accessibility. Besides current hospital-based prevention and pharmaceutical control measures, mass education campaigns, lifestyle interventions etc., emphasis should be given to the role of family doctor as a primary-care health provider.

Entities:  

Keywords:  Control; Type-II diabetics; arterial hypertension; dyslipidemia

Year:  2014        PMID: 25006533      PMCID: PMC4082230     

Source DB:  PubMed          Journal:  Am J Cardiovasc Dis        ISSN: 2160-200X


  36 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.

Authors:  G Nickenig; A T Bäumer; Y Temur; D Kebben; F Jockenhövel; M Böhm
Journal:  Circulation       Date:  1999-11-23       Impact factor: 29.690

3.  The need for improved medical management of patients with concomitant hypertension and type 2 diabetes mellitus.

Authors:  Paul J Godley; Susan K Maue; Eileen W Farrelly; Feride Frech
Journal:  Am J Manag Care       Date:  2005-04       Impact factor: 2.229

4.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

5.  Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies.

Authors:  Pamela B DeGuzman; Kwame O Akosah; Allan G Simpson; Kirk E Barbieri; Gregory C Megginson; Randal I Goldberg; George A Beller
Journal:  Diab Vasc Dis Res       Date:  2012-01-10       Impact factor: 3.291

6.  Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis.

Authors:  Lauren C Brown; Jeffrey A Johnson; Sumit R Majumdar; Ross T Tsuyuki; Finlay A McAlister
Journal:  CMAJ       Date:  2004-11-09       Impact factor: 8.262

Review 7.  Insulin resistance and hypertension.

Authors:  James R Sowers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-05       Impact factor: 4.733

8.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

Review 9.  Interactions between hypercholesterolemia and hypertension: implications for therapy.

Authors:  Claudio Borghi
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-09       Impact factor: 2.894

10.  Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008.

Authors:  Andreas Kuznik; Jack Mardekian
Journal:  Cardiovasc Diabetol       Date:  2011-04-17       Impact factor: 9.951

View more
  1 in total

1.  Patient-level factors influencing hypertension control in adults in Accra, Ghana.

Authors:  Darlene Esinam Okai; Adom Manu; Emefa Modey Amoah; Amos Laar; Joseph Akamah; Kwasi Torpey
Journal:  BMC Cardiovasc Disord       Date:  2020-03-11       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.